Teva Settles Mississippi Allegations of Price-Fixing Collusion in the Generic Drugs Market

  • Mississippi AG Lynn Finch reached a settlement with Teva Pharmaceuticals USA, Inc. (“Teva”) to resolve allegations of price fixing and market allocation for numerous generic drugs in violation of the Sherman Act.
  • The settlement stems from a 2019 complaint by 43 state AGs, and the Puerto Rico AG, against Teva and more than a dozen rivals, as well as related individual pharmaceutical executives, alleging that they colluded to divide the generic pharmaceutical customer base to artificially inflate prices in a coordinated manner for drugs used to treat numerous conditions, including multiple sclerosis, HIV, ADHD, kidney disease, and cancer, among other things.
  • Under the terms of the settlement, Teva will pay $925,000 to Mississippi for the voluntary dismissal of Mississippi’s claims in the 2019 case and other related cases.